RATIONALE: The immunological and protective role of pneumococcal carriage in healthy adults is not known, but high rates of disease and death in the elderly are associated with low carriage prevalence. OBJECTIVES: We employed an experimental human pneumococcal carriage model to investigate the immunizing effect of a single carriage episode. METHODS: Seventy healthy adults were challenged, and of those with carriage, 10 were rechallenged intranasally with live 6B Streptococcus pneumoniae up to 11 months after clearance of the first carriage episode. Serum and nasal wash antibody responses were measured before and after each challenge. MEASUREMENTS AND MAIN RESULTS: A total of 29 subjects were experimentally colonized. No subjects were colonized by experimental rechallenge, demonstrating the protective effect of initial carriage against subsequent infection. Carriage increased both mucosal and serum IgG levels to pneumococcal proteins and polysaccharide, resulting in a fourfold increase in opsonophagocytic activity. Importantly, passive transfer of postcarriage sera from colonized subjects conferred 70% protection against lethal challenge by a heterologous strain in a murine model of invasive pneumococcal pneumonia. These levels were significantly higher than the protection conferred by either precarriage sera (30%) or saline (10%). CONCLUSIONS: Experimental human carriage resulted in mucosal and systemic immunological responses that conferred protection against recolonization and invasive pneumococcal disease. These data suggest that mucosal pneumococcal vaccination strategies may be important for vulnerable patient groups, particularly the elderly, who do not sustain carriage.
RATIONALE: The immunological and protective role of pneumococcal carriage in healthy adults is not known, but high rates of disease and death in the elderly are associated with low carriage prevalence. OBJECTIVES: We employed an experimental human pneumococcal carriage model to investigate the immunizing effect of a single carriage episode. METHODS: Seventy healthy adults were challenged, and of those with carriage, 10 were rechallenged intranasally with live 6B Streptococcus pneumoniae up to 11 months after clearance of the first carriage episode. Serum and nasal wash antibody responses were measured before and after each challenge. MEASUREMENTS AND MAIN RESULTS: A total of 29 subjects were experimentally colonized. No subjects were colonized by experimental rechallenge, demonstrating the protective effect of initial carriage against subsequent infection. Carriage increased both mucosal and serum IgG levels to pneumococcal proteins and polysaccharide, resulting in a fourfold increase in opsonophagocytic activity. Importantly, passive transfer of postcarriage sera from colonized subjects conferred 70% protection against lethal challenge by a heterologous strain in a murine model of invasive pneumococcal pneumonia. These levels were significantly higher than the protection conferred by either precarriage sera (30%) or saline (10%). CONCLUSIONS: Experimental human carriage resulted in mucosal and systemic immunological responses that conferred protection against recolonization and invasive pneumococcal disease. These data suggest that mucosal pneumococcal vaccination strategies may be important for vulnerable patient groups, particularly the elderly, who do not sustain carriage.
Authors: S Romero-Steiner; D Libutti; L B Pais; J Dykes; P Anderson; J C Whitin; H L Keyserling; G M Carlone Journal: Clin Diagn Lab Immunol Date: 1997-07
Authors: Richard Malley; Krzysztof Trzcinski; Amit Srivastava; Claudette M Thompson; Porter W Anderson; Marc Lipsitch Journal: Proc Natl Acad Sci U S A Date: 2005-03-21 Impact factor: 11.205
Authors: I Ridda; C R Macintyre; R Lindley; P B McIntyre; M Brown; S Oftadeh; J Sullivan; G L Gilbert Journal: Vaccine Date: 2010-04-14 Impact factor: 3.641
Authors: Qibo Zhang; Jolanta Bernatoniene; Linda Bagrade; James C Paton; Timothy J Mitchell; Sven Hammerschmidt; Desmond A Nunez; Adam Finn Journal: Infect Immun Date: 2006-08 Impact factor: 3.441
Authors: Adriana T Moreno; Maria Leonor S Oliveira; Daniela M Ferreira; Paulo L Ho; Michelle Darrieux; Luciana C C Leite; Jorge M C Ferreira; Fabiana C Pimenta; Ana Lúcia S S Andrade; Eliane N Miyaji Journal: Clin Vaccine Immunol Date: 2010-01-20
Authors: Tera L McCool; Thomas R Cate; Elaine I Tuomanen; Peter Adrian; Tim J Mitchell; Jeffrey N Weiser Journal: Infect Immun Date: 2003-10 Impact factor: 3.441
Authors: Adam K A Wright; Daniela M Ferreira; Jenna F Gritzfeld; Angela D Wright; Kathryn Armitage; Kondwani C Jambo; Emily Bate; Sherouk El Batrawy; Andrea Collins; Stephen B Gordon Journal: PLoS Pathog Date: 2012-04-05 Impact factor: 6.823
Authors: Hugh Adler; Esther L German; Elena Mitsi; Elissavet Nikolaou; Sherin Pojar; Caz Hales; Rachel Robinson; Victoria Connor; Helen Hill; Angela D Hyder-Wright; Lepa Lazarova; Catherine Lowe; Emma L Smith; India Wheeler; Seher R Zaidi; Simon P Jochems; Dessi Loukov; Jesús Reiné; Carla Solórzano-Gonzalez; Polly de Gorguette d'Argoeuves; Tessa Jones; David Goldblatt; Tao Chen; Stephen J Aston; Neil French; Andrea M Collins; Stephen B Gordon; Daniela M Ferreira; Jamie Rylance Journal: Am J Respir Crit Care Med Date: 2021-03-01 Impact factor: 21.405
Authors: Rituparna Das; Meredith I LaRose; Christopher B Hergott; Lin Leng; Richard Bucala; Jeffrey N Weiser Journal: J Immunol Date: 2014-06-13 Impact factor: 5.422
Authors: Elsa N Bou Ghanem; Nang H Tin Maung; Nalat Siwapornchai; Aaron E Goodwin; Stacie Clark; Ernesto J Muñoz-Elías; Andrew Camilli; Rachel M Gerstein; John M Leong Journal: J Immunol Date: 2018-04-16 Impact factor: 5.422
Authors: Daniel R Neill; William R Coward; Jenna F Gritzfeld; Luke Richards; Francesc J Garcia-Garcia; Javier Dotor; Stephen B Gordon; Aras Kadioglu Journal: Am J Respir Crit Care Med Date: 2014-05-15 Impact factor: 21.405